Neuphoria Therapeutics (NEUP) Gains from Investment Securities (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Gains from Investment Securities of $842872.0 for Q1 2026, up 128.69% year-over-year from $368567.0 in Q1 2025, and up 115.67% quarter-over-quarter from -$5.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Gains from Investment Securities for 4 consecutive years, with $842872.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 128.69% year-over-year to $842872.0; the TTM figure through Mar 2026 stood at $1.7 million (up 131.94% YoY), while the FY2025 annual figure was -$956340.0, up 48.82% from the prior year.
- Gains from Investment Securities grew to $842872.0 in Q1 2026 per NEUP's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.4 million in Q3 2025 and bottomed at -$5.4 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged -$270055.7 across 4 years, with a median of $124558.0 in 2023.
- On a YoY basis, Gains from Investment Securities climbed as much as 2837.96% in 2024 and fell as far as 2481.42% in 2024.
- Neuphoria Therapeutics' Gains from Investment Securities stood at -$114459.0 in 2023, then soared by 2837.96% to $3.1 million in 2024, then tumbled by 271.66% to -$5.4 million in 2025, then soared by 115.67% to $842872.0 in 2026.
- Business Quant data shows NEUP's Gains from Investment Securities at $842872.0 in Q1 2026, -$5.4 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 842,872.00 |
| Mar 31, 2026 | 842,872.00 |
| Dec 31, 2025 | -5.38 Mn |
| Dec 31, 2025 | -5.38 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | -2.97 Mn |
| Sep 30, 2024 | -2.97 Mn |
| Jun 30, 2024 | -2.45 Mn |
| Jun 30, 2024 | -2.45 Mn |
| Mar 31, 2024 | 574,200.00 |
| Mar 31, 2024 | 574,200.00 |
| Dec 31, 2023 | -114,459.00 |
| Dec 31, 2023 | -114,459.00 |